AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

UCB

Major Shareholding Notification Mar 12, 2025

4017_mrq_2025-03-12_ca5b145e-ac79-4638-9a57-675cad3a020f.pdf

Major Shareholding Notification

Open in Viewer

Opens in native device viewer

Transparency notification BlackRock, Inc.

Brussels (Belgium), 12 March 2025 – 20:00 (CEST)Regulated information

1. Summary of the notification

Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it received a transparency notification from BlackRock, Inc. (having its registered office at 50 Hudson Yards, New York, NY, 10001, U.S.A.), on 11 March 2025.

BlackRock, Inc. notified that, following an acquisition of UCB shares with voting rights by its affiliates, its shareholding in UCB SA increased and crossed the 5% threshold upwards on 10 March 2025.

On 10 March 2025, BlackRock, Inc. (taking into account the holding of its affiliates) owned 9 725 971 UCB shares with voting rights and 126.101 assimilated financial instruments, representing together 5.07% of the total number of shares issued by the company (194 505 658), versus 5.10% (9 699 063 UCB shares and 215 582 assimilated financial instruments) in the previous notification dated 7 March 2025.

2. Content of the notification

  • Reason for the notification: Acquisition or disposal of voting securities or voting rights.
  • Notification by: A parent undertaking or a controlling person.
  • Persons subject to the notification requirement:
Name Address (for legal entities)
BlackRock, Inc. 50 Hudson Yards, New York, NY, 10001, U.S.A.
BlackRock (Netherlands) B.V. Rembrandt Tower, 17th floor, Amstelplein, Amsterdam, Netherlands
BlackRock (Singapore) Limited 20 Anson Road #18-01, Singapore, 79912, Singapore
BlackRock Advisors (UK) Limited 12 Throgmorton Avenue, London, EC2N 2DL, U.K.
BlackRock Advisors, LLC 50 Hudson Yards, New York, NY, 10001, U.S.A.
BlackRock Asset Management Canada Limited 161 Bay Street, Suite 2500, Toronto, Ontario, M5J 2S1, Canada

BlackRock Asset Management Deutschland AG Lenbachplatz 1 1st Floor, Munich, 80333-MN3, Germany
BlackRock Asset Management North Asia
Limited
15/F, 16/F, 17/F Citibank Tower & 17/F ICBC Tower, 3 Garden Road,
Central, Hong Kong
BlackRock Financial Management, Inc. 50 Hudson Yards, New York, NY, 10001, U.S.A.
BlackRock Fund Advisors 400 Howard Street, San Francisco, CA, 94105, U.S.A.
BlackRock
Institutional
Trust
Company,
National Association
400 Howard Street, San Francisco, CA, 94105, U.S.A.
BlackRock
Investment
Management
(Australia) Limited
Level 37 Chifley Tower, 2 Chifley Square, Sydney NSW 2000, Australia
BlackRock
Investment
Management
(UK)
Limited
12 Throgmorton Avenue, London, EC2N 2DL, U.K.
BlackRock Investment Management, LLC 1 University Square Drive, Princeton, NJ, 8540, U.S.A.
BlackRock Japan Co., Ltd. 1-8-3 Marunouchi Chiyoda-ku, Trust Tower Main, Tokyo, 100-8217,
Japan
Aperio Group, LLC 3 Harbor Dr Suite 204, Sausalito, CA 94965, U.S.A.
SpiderRock Advisors, LLC Corporation Service Company, 251 Little Falls Drive, Wilmington, DE
19808, U.S.A.
  • Date on which the threshold is crossed: 10 March 2025.
  • Threshold crossed (in %): 5%.
  • Denominator: 194 505 658.

Notified details:

A) Voting rights Previous notification After the transaction
# of voting rights # of voting rights % of voting rights
Holders of voting rights Linked to
securities
Not linked to
the securities
Linked to
securities
Not linked to
the
securities
BlackRock, Inc. 0 0 0,00%
BlackRock (Netherlands)
B.V.
1.337 1.337 0,00%
BlackRock (Singapore)
Limited
10.538 9.601 0,00%
BlackRock Advisors (UK)
Limited
1.623.556 1.622.142 0,83%
BlackRock Advisors, LLC 201.535 201.535 0,10%
BlackRock Asset
Management Canada
Limited
138.714 138.719 0,07%
BlackRock Asset
Management Deutschland
AG
181.285 179.060 0,09%
BlackRock Asset
Management North Asia
Limited
3.080 3.080 0,00%
BlackRock Financial
Management, Inc.
73.923 73.923 0,04%
BlackRock Fund Advisors 2.445.575 2.447.918 1,26%
BlackRock Institutional
Trust Company, National
Association
1.602.340 1.601.607 0,82%
BlackRock Investment
Management (Australia)
Limited
51.478 51.564 0,03%

UCB News

BlackRock Investment
Management (UK) Limited
2.508.775 2.550.434 1,31%
BlackRock Investment
Management, LLC
645.042 633.166 0,33%
BlackRock Japan Co., Ltd. 170.111 170.111 0,09%
Aperio Group, LLC 41.774 41.774 0,02%
Subtotal 9.699.063 9.725.971 5,00%
TOTAL 9.725.971 0 5,00% 0,00%
B) Equivalent
financial
instruments
After the transaction
Holders of
equivalent
financial
instruments
Type of financial instrument Expiration
date
Exercise
period
or date
# of
voting
rights that
may be
acquired if
the
instrument
is
exercised
% of
voting
rights
Settlement
BlackRock Investment
Management (UK)
Limited
Securities Lent 113.548 0,06% physical
BlackRock Investment
Management, LLC
Securities Lent 2.954 0,00% physical
BlackRock Financial
Management, Inc.
Contract Difference 1.165 0,00% cash
BlackRock
Institutional Trust
Company, National
Association
Contract Difference 2.148 0,00% cash
BlackRock Investment
Management (UK)
Limited
Depositary Receipt 229 0,00%

Aperio Group, LLC Depositary Receipt 6.024 0,00%
SpiderRock Advisors,
LLC
Depositary Receipt 33 0,00%
TOTAL 126.101 0,06%
TOTAL (A & B) # of voting
rights
% of voting
rights
CALCULATE 9.852.071 5,07%
  • Chain of controlled undertakings through which the holding is effectively held: Please see the full chain of control in the 'Chain of Control' tab.
  • Additional information: The disclosure obligation arose due to voting rights attached to shares for BlackRock, Inc going above 5%

3. Further information

This press release and the detailed transparency notification are available on UCB SA/NV's website via the following link.

An updated overview of the UCB SA/NV large shareholdings will be available on UCB SA/NV's website via the following link.

For further information, contact UCB:

Investor Relations Antje Witte T +32 2 559 94 14 [email protected]

Corporate Communications Laurent Schots T+32 2 559 92 64 [email protected]

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 9 000 people in approximately 40 countries, the company generated revenue of € 6.1 billion in 2024. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news

Talk to a Data Expert

Have a question? We'll get back to you promptly.